Can a Greek pharmaceutical industry help Europe to ensure adequacy of drugs and active substances by acquiring autonomy from third countries in the health sector? Demo aspires to succeed.

The largest investment plan of the industry

Thanks to a six-year (2021-2027) multi-dimensional investment plan, the largest exporter of injectable drugs in Greece is preparing to climb track and enter the biotechnology and production of monoclonal antibodies, as well as raw materials and medicines.

An investment program to bring to Greece added value of more than one billion euros and thousands of jobs over a decade.

Autonomy in the production of drugs

China and India today hold about 60% of world production of active substances and their respective generics. Who can forget the lack of basic drugs in Europe during the Covid-19 period due to Lockdowns in these countries. In order not to be in the same difficult position again, the EU redefined its policy, aiming to boost the production of drugs on European soil. Demo’s goal is to cover a significant part of this vacuum, Developing and factor in Greece for the first time in Greece medicinal products and active substances of chemical origin.

Tripoli’s productive unit

The demo aspires to gradually secure drugs in Greece and Europe through the Productive Unit he creates in Tripoli and will aim to produce raw materials in large quantities. Based on the investment plan, it will be able to cover 34% of the EU needs of peniciline medicines and 35% on oncology. The HUB of Tripoli will be powered by research activity at the Research and Development Center in Thermi, Thessaloniki, aimed at developing 5 new raw materials and 21 final pharmaceuticals each year

Investment in research and development

It is about the largest center of pharmaceutical research and development In the area with 13 separate workshops, high training scientific staff and state of the art equipment. It is indicative that the Demo R&D Center in Thermi operates the only Nuclear Magnetic Coordination Laboratory (NMR) in a non -academic area in Greece. A laboratory that allows the structure of organic molecules to be imprinted and identified.

For the first time a biotechnology development in Greece

And it’s not just chemicals. Demo listening to the future becomes The first pharmaceutical industry in Greece to invest in biotechnology. Monoclonal antibodies, recombinant proteins and hormones for the treatment of cancer, autoimmune, hereditary, incurable and rare diseases, MRNA and DNA vaccines, gene and cell therapies gradually occupy a growing market share. Now 60% of all new drugs are organic and according to forecasts, in 2030, consumption of worldwide will be 70% in organic drugs and 30% in chemicals.

Biotechnology Research Center & Life-Academy

Catching the wave the demo Creates a modern research center in Agios Stefanos Attica. This standard unit will produce monoclonal antibodies intended for clinical trials. By 2027, the research and development of three monoclonal antibodies are planned, two of which for the biological treatment of malignant neoplasms. Invested in extroversion, DEMO will also enable start up companies abroad to produce their trials for clinical trials in Greece.

At the same time, DEMO Creates in Kryoneri Attica Life-Academyin which a mixture of scientists from abroad will be trained by young scientists from Greek universities to make the research and development pocket in this new technology.

Demo - biotechnology

DEMO’s 2023-2032 biotechnology program includes organized development of biotechnological drugs on a commercial scale for the first time in Greece.

The imprint on the national economy

By creating the biological drug production industry in Greece, DEMO contributes to the country’s brain gain, creates the conditions for increasing national revenue in the field of clinical trials and laying the foundations to ensure the adequacy of the national health system and biotechnological drugs.